Quick Summary
Researchers compared immune cell patterns and stress markers in blood samples from people with long COVID, ME/CFS, and healthy controls. They observed that specific types of T cells and oxidative stress markers were associated with both conditions, though the patterns differed between them. The study reports these differences were more pronounced in ME/CFS than in long COVID, but it remains unclear whether these markers explain why symptoms occur or whether they could help diagnose these conditions in clinical practice.
Why It Matters
This study contributes to understanding immune dysregulation in ME/CFS by identifying specific T-cell subsets and oxidative stress markers associated with the condition, potentially aiding disease characterisation. The finding that ME/CFS shows stronger biomarker separation from healthy controls than long COVID suggests biological differences between these overlapping conditions, which may have implications for differential diagnosis and future mechanistic research. However, the study does not establish whether these markers cause symptoms or could be used clinically to diagnose ME/CFS.
Observed Findings
What the study reports it measured.
- A five-marker signature (Th17, CD15s+CD161−eTreg, CD161+ Treg) was associated with ME/CFS and long COVID, with stronger separation of ME/CFS from healthy controls (AUC 0.907–0.924) than long COVID from healthy controls (AUC 0.577–0.727).
- Altered T-cell subsets were associated with markers of oxidative stress (GPX1) and nitrosative stress (NOS3) in both patient groups.
- Malondialdehyde (MDA) was independently associated with classification in three-way comparisons, while glutathione peroxidase 1 (GPX1) differentiated ME/CFS from long COVID.
- T-cell subset alterations were not directly associated with clinical symptom severity scores (HAMA, HAMD, FF, dePol) in the cohorts studied.
Inferred Conclusions
What the authors interpret from those results.
- The authors interpret these results as suggesting that long COVID and ME/CFS share markers of oxidative stress and T-cell dysregulation but differ in the extent of cellular damage and exhaustion of compensatory mechanisms.
- They propose that the stronger biomarker separation observed in ME/CFS may reflect more robust or distinct immune endotyping, though they acknowledge that differences in disease duration, vaccination history, and cohort composition could contribute to classification differences.
- The dissociation between altered immune markers and symptom severity is interpreted as indicating that immune dysregulation may not directly translate to symptom intensity, or that other unmeasured factors mediate this relationship.
Remaining Questions
- Does the observed association between T-cell alterations and oxidative stress reflect a causal relationship, or are both consequences of a shared underlying process?
- Can the five-marker signature be validated in independent cohorts and used as a diagnostic or prognostic tool in clinical settings?
- Why do altered T-cell subsets and oxidative stress markers not correlate directly with symptom severity, and what other biological or clinical factors might bridge this gap?
- Does the proposed difference in 'exhaustion of compensatory mechanisms' between long COVID and ME/CFS reflect distinct pathophysiology, or partly reflect differences in disease duration, recovery rate, and vaccination exposure between cohorts?
What This Study Does Not Prove
This cross-sectional design does not establish causation between altered T-cell subsets and ME/CFS symptoms, nor does it prove that these biomarkers drive disease pathophysiology. The observed association between T-cell markers and oxidative stress does not confirm that oxidative stress is a mechanistic driver of immune dysregulation. The study does not demonstrate clinical utility of a five-marker signature for diagnosis, nor does it validate findings in independent cohorts.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Todorova, Yana, Dimitrova, Radostina, Kalfova, Teodora, Petrov, Steliyan, Bozhkova, Martina, Ivanovska, Mariya, et al. (2026). Treg and Oxidative Stress Biomarker Profiles in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.. International journal of molecular sciences. https://doi.org/10.3390/ijms27219422
BibTeX
@article{mecfsatlas-todorova-2026-treg-oxidative,
author = {Todorova, Yana and Dimitrova, Radostina and Kalfova, Teodora and Petrov, Steliyan and Bozhkova, Martina and Ivanovska, Mariya and Dudova, Dobrina and Murdjeva, Mariana and Taskov, Hristo and Maes, Michael and Nikolova, Maria},
title = {Treg and Oxidative Stress Biomarker Profiles in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.},
journal = {International journal of molecular sciences},
year = {2026},
doi = {10.3390/ijms27219422},
note = {PubMed: 43027675},
url = {https://www.mecfsatlas.com/evidence/todorova-2026-treg-oxidative},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/todorova-2026-treg-oxidative
Contribute
Private, reviewed by a human. Not a public comment thread.